XGN News and Press, Exagen Inc. From 04/28/25

2025-04-28 09:19:20 ET More on Exagen Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Exagen Historical earnings data for Exagen ...

$25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital CARLSBAD, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solution...

2025-04-26 03:31:32 ET Summary We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's recent momentum, modest valuation, and potential u...

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen’s President and Chief Executive...

2025-03-11 13:13:02 ET Exagen Inc. (XGN) Q4 2024 Results Conference Call March 11, 2025 08:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black - Chief Financial Officer Conference ...

2025-03-11 08:04:15 ET More on Exagen Seeking Alpha’s Quant Rating on Exagen Historical earnings data for Exagen Financial information for Exagen Read the full article on Seeking Alpha For further details see: Exagen GAAP EPS of -$0.20 beat...

Delivered record full-year total revenue and AVISE CTD average selling price Improved full-year adjusted EBITDA loss and cash use by over 40% Commercialized new biomarkers to enhance clinical utility of AVISE CTD CARLSBAD, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (...

Algoma Steel Group Inc. (ASTL) is expected to report $0.06 for Q3 2025 E.W. Scripps Company (The) (SSP) is expected to report for Q4 2024 TransAct Technologies Incorporated (TACT) is expected to report $-0.1 for Q4 2024 Kindly MD, Inc. (KDLY) is expected to report for Q4 2024 Talo...

CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024, before the market opens on Tuesday, March 11, 2025. John Aballi, Exagen’s President and ...

CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences: BTIG at Snowbird: MedTech, Digital Health, Life Science & D...